Articles tagged with Sarcoma
Researchers find that targeting Trk and IGF1R pathways can delay Ewing sarcoma tumor growth, but effect is temporary. NTRK gene expression associations with patient OS were found, indicating potential biomarker value.
A study identifies curcumin as the natural compound with the most balanced combination of anticancer activity and safety against fibrosarcoma cells. Curcumin, along with berberine, disrupts mitochondrial function and energy metabolism in cancer cells, leading to cellular senescence and death.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Researchers at the University of Calgary have developed a novel CAR T-cell therapy called GCAR1, showing strong preclinical and early clinical promise in treating sarcoma and other cancers. The therapy has been tested on two Canadian patients, with one patient experiencing significant prolongation of life expectancy by 18 months.
Researchers develop novel PROTACs to target molecular drivers of cancer, showing effectiveness against aggressive tumor cells and limited side effects. The new approach offers a promising strategy for treating treatment-resistant cancers and improving survival rates.
Researchers seek to understand the biological mechanisms behind Ewing sarcoma's rapid growth and spread, developing new tools to visualize DNA structures and regulate gene expression. This could lead to personalized cancer treatments targeting specific molecules for improved patient outcomes.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.
The Sylvester Cancer Institute has made significant breakthroughs in multiple myeloma treatment with the immunotherapy drug teclistamab, which extends remission and survival rates. Additionally, research has shed light on glioma evolution after treatment and identified genetic markers for aggressive solitary fibrous tumors.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
The center is the first in the region to offer TCR-T therapy, an FDA-approved treatment targeting proteins inside cancer cells. Patients with chemotherapy-resistant synovial sarcoma can now access this novel cellular therapy.
The University of Texas at San Antonio has received significant funding from the Cancer Prevention and Research Institute of Texas to develop innovative cancer research technologies and treatments. The institution will focus on pressing cancers such as Ewing sarcoma, obesity-related endometrial cancer risk, and AI in clinical oncology.
Researchers identified specific gene fusion patterns linked to more aggressive disease behavior and increased risk of metastasis in solitary fibrous tumors. The study suggests that these molecular differences could serve as potential biomarkers for predicting patient outcomes and guiding treatment decisions.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
Researchers found that combining targeted radiation therapy with BO-112 and anti-PD-1 therapy before surgery activated the immune system to fight cancer. This approach reshaped the tumor microenvironment to support T-cell activity, resulting in fewer cancer cells and a more effective anti-tumor response.
Researchers develop new approach to prevent chemotherapy-related leukemia by analyzing blood samples from four clinical trials, showing a 26-36% reduction in blood cell growth with mutated TP53 gene. They also discover that monoclonal antibodies can turn neutrophils into cancer killers and induce tumor eradication in preclinical models.
The National Comprehensive Cancer Network has published new guidelines for Pediatric Soft Tissue Sarcomas, highlighting the unique characteristics of this childhood cancer. The guidelines focus on rhabdomyosarcoma (RMS), a subtype with varying genetic changes that influence treatment outcomes.
Researchers at Penn Vet have shown that trained dogs can identify the odor of hemangiosarcoma, a malignant cancer of blood vessel cells, with an accuracy rate of 70%. Early detection could lead to better outcomes, including prevention of disease spread and earlier removal of the spleen or initiation of chemotherapy.
A new study from Fox Chase Cancer Center confirms that preoperative radiation therapy does not reduce surgical complexity in patients with retroperitoneal sarcoma. The research suggests that most patients benefit from proceeding directly to surgery, as skipping radiation has no significant impact on tumor size or surgical outcomes.
A global review of COVID-19 vaccination and infection cases found associations between the two and certain types of cancer. The study analyzed 69 publications and identified potential biological mechanisms, including immune responses and inflammation.
A new Curtin University study reveals that people diagnosed with sarcoma, a rare and complex cancer, are being left without the resources they urgently need. The research found that many online resources significantly lacked emotional support, practical guidance, age-specific information, and dedicated resources for caregivers.
Researchers identified a targeted drug that blocks a specific genetic pathway to reverse tumor-driving cellular interactions, potentially restoring DNA function and benefiting patients with synovial sarcoma. The study's findings endorse a promising strategy to improve outcomes for this rare but deadly cancer.
Researchers create novel antibody-based treatment that combines diagnostic and therapeutic capabilities to target LRRC15-expressing tumors, slowing growth and extending survival. The approach shows promise in preclinical models by priming tumors for immune response and boosting immunotherapy's effectiveness.
Researchers at Fox Chase Cancer Center found adaptive radiation therapy can reduce radiation to healthy tissue by 21% while delivering higher doses to tumors. The study offers new hope for patients with previously untreatable cancers.
A new targeted radiation approach has achieved a near-complete response in three patients with solitary fibrous tumor (SFT), a rare and aggressive form of cancer. The therapy significantly reduced cancer activity and provided symptom relief, highlighting its potential as a treatment option.
Adult fibrosarcoma is a rare and highly aggressive malignancy requiring precise diagnosis and multimodal treatment. The case report emphasizes the need for early detection, complete surgical removal, and tailored postoperative care to improve outcomes in patients with this type of tumor.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that using a drug as a blocker to outcompete the SUMO2 protein may be a winning strategy against synovial sarcoma. This approach aims to reverse aberrant epigenetic rewiring driven by the SS18::SSX fusion oncoproteins and impair sarcomagenesis.
Researchers found a unique microbial signature in colorectal cancer samples that can accurately distinguish them from other types of cancer. This discovery has the potential to improve diagnosis and treatment outcomes for patients with colorectal cancer.
Researchers at U. Iowa identify a specific metabolic pathway that fuels tumor growth in MPNST, providing a promising new target for treatment. By blocking this pathway, tumors grow more slowly and are more vulnerable to chemotherapy.
Researchers at UCLA have successfully created a continuous supply of functional T cells using genetically engineered stem cells. This breakthrough could lead to longer-lasting protection against cancer and potentially treat other diseases such as HIV or autoimmune disorders.
Researchers highlight microRNAs as crucial biomarkers for diagnosing and monitoring soft tissue sarcomas, with potential for precision medicine. MicroRNAs could help distinguish between tumor types and guide treatment decisions.
Researchers at Ohio State University have developed blood tests to diagnose pancreatic cancer and predict treatment outcomes. Genetic information can also help predict breast cancer survival rates, while a new blood test may improve treatment response for patients with advanced sarcoma. These findings offer promising tools for early de...
Researchers at Fox Chase Cancer Center found that fragmented care does not negatively impact survival outcomes for retroperitoneal sarcoma patients. Despite longer travel distances and delays between diagnosis and treatment, patients receiving nonfragmented care had equivalent overall survival rates as those with non-fragmented care.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers at Osaka Metropolitan University found that plasma-activated medium reduces synovial sarcoma tumor growth in human cells and mice, with no obvious side effects. The treatment was verified through in vitro and in vivo tests, offering a new potential treatment option for this rare form of cancer.
Researchers have developed an AI-driven model that can accurately diagnose various subtypes of pediatric sarcoma using only routine pathology images. The model correctly distinguished between nine sarcoma subtypes, demonstrating its potential to provide quick and accurate cancer diagnoses in under-resourced settings.
NGR Oncology has created a new Sarcoma Subcommittee to improve outcomes for adults with cancer, focusing on building a robust program, collaborating with the Children's Oncology Group, and promoting sarcoma research. The subcommittee is led by Chair Dian Wang, MD, PhD, and Vice-Chairs William Tseng, MD, and Brian A Van Tine, MD, PhD.
The ESMO Sarcoma and Rare Cancers Congress 2025 will bring together experts to present and discuss developments in diagnosing and treating rare solid tumours. The event will focus on immunotherapy, global challenges, and opportunities for international collaboration.
A team led by Prof. Woo Young Jang developed a novel fluorescent probe to visualize cancer stem cells in complex samples, offering a new direction for cancer diagnostic imaging. This technology has significant implications for diagnosing and monitoring sarcomas.
Researchers aim to identify key mechanisms and molecular targets to prevent tumor progression in Rhabdomyosarcoma patients. The study focuses on the TAK1 protein, which plays a significant role in regulating cell growth, and its potential inhibition as a therapeutic approach.
Two comprehensive datasets from the Gabriella Miller Kids First Pediatric Research Program explore childhood cancers and congenital disorders. The new datasets aim to identify genetic causes and links between these diseases in children, ultimately supporting the development of improved treatments.
Researchers found lower incidence rates of soft tissue sarcomas among young U.S. active-duty military servicemen compared to the general population, likely due to better health and early detection within the military health system. In contrast, middle-aged servicemen showed higher rates, possibly due to greater cumulative exposure to t...
Ewing sarcoma, a rare childhood cancer, is made more aggressive by the absence of STAG2 protein. This discovery provides potential biomarkers and therapeutic targets for treatment.
A new clinical trial found that the addition of immunotherapy drug pembrolizumab to standard treatment improved disease-free survival rates for patients with stage 3 soft tissue sarcoma. The study showed that pembrolizumab reduced recurrence or death for patients by 15 percentage points compared to standard treatment.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers report a case of undifferentiated spindle cell sarcoma with primary insensitivity to standard chemotherapy, but a pronounced response to BRAF/MEK inhibitors at recurrence. The tumor was found to be BRAF exon 15 double-mutated: c.1799T>A p.V600E and c.1819T>A p.S607T.
Researchers found that FAP-targeted radioligand therapy controlled disease progression in nearly half of patients with advanced sarcoma, and was well-tolerated without critical organ radiation dose levels being reached. The study's results indicate a promising approach for this patient group with limited treatment options.
A University of California - Riverside study finds that medium-sized dogs have a higher risk of developing cancer than larger or smaller breeds. The multistage model of cancer acquisition supports this finding, suggesting that size is a major risk factor for cancer.
Researchers at UNC Lineberger Comprehensive Cancer Center have developed a mouse model of Kaposi sarcoma, which could facilitate the development of new drugs to treat the disease. The model provides a better understanding of angiogenesis and its potential targets for therapy.
Researchers used machine learning tools to map distinct cellular configurations in soft tissue sarcomas, identifying correlations between cell types and clinical outcomes. The analysis uncovered three multicellular communities that correlated with patients' prognoses, potentially informing treatment decisions.
A team of researchers from Kyoto University has developed a microfluidic co-culture vasculature chip that mimics the microenvironment of alveolar soft part sarcoma (ASPS), a rare cancer. The chip enables scientists to study cell-to-cell interactions and angiogenic mechanisms, which may lead to new strategies for treating ASPS patients.
Researchers found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. A pharmacological inhibitor of USP1 activated cdc42 and inhibited Ewing sarcoma growth.
A Phase II trial found that neoadjuvant immunotherapy significantly reduced residual tumor and improved overall survival for patients with undifferentiated pleomorphic sarcoma, with 90% having less than 15% viable tumor cells remaining. The treatment approach is a promising option for patients with limited systemic therapy options.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
Researchers from MD Anderson Cancer Center reported a case of a patient with an exceptional response to pazopanib treatment for over 5 years. The study shows that pazopanib prevents or delays the progression of additional metastasis in EWSR1-NFATC2 positive sarcomas. Further studies are warranted.
Researchers at Cold Spring Harbor Laboratory have made a significant breakthrough in transforming rhabdomyosarcoma cells into regularly functioning muscle cells using differentiation therapy. This innovative approach has the potential to spare patients and their families from pain and suffering by offering a new treatment option.
Researchers report a case of a 15-year-old boy with recurrent intrathoracic synovial sarcoma who achieved partial response with BRAF inhibitor Vemurafenib treatment. The study highlights the importance of routine next-generation sequencing to drive treatment choice and investigate BRAF mutations in SS tumors.
The NRG Oncology combined trial results indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma. pCR can be used as a prognostic factor for clinical outcomes in future STS research, with patients achieving higher overall and disease-free survival rates.